MRI引导放疗治疗局限性前列腺癌需降低毒性才能具有成本效益
本研究通过文献值与两家机构成本核算,比较MRI引导放疗与CT引导放疗在常规39次和SBRT 5次方案中的成本,并用Markov模型计算每降低1%急慢性毒性所节省的费用。结果显示,SBRT需相对降低毒性7%和14%才能在每QALY 10万和5万美元阈值下具有成本效益,常规分割放疗则需降低50%和94%。
要点
- SBRT方案中MR-IGRT每疗程增加成本1459美元,常规分割放疗每疗程增加10129美元。
- SBRT在每QALY 10万和5万美元阈值下分别需相对降低毒性7%和14%才具成本效益。
- 常规分割放疗需相对降低毒性50%和94%才具成本效益。
核心结论
- 从医疗保健视角看,MR-IGRT可合理预期具有成本效益。
- 大分割方案如5次SBRT最可能具有成本效益,因其仅需轻微降低毒性(7-14%)。
研究设计与样本
- 研究类型为经济评估,采用文献值和两家机构的成本核算确定MR-IGRT与CT-IGRT在常规39次和SBRT 5次方案中的成本。
- 从20项研究汇总CT-IGRT相关的胃肠和泌尿生殖毒性率,毒性相关成本和效用值来自文献值和成本数据库。
- 使用Markov模型确定MR-IGRT相对降低急慢性毒性每1%时15年内每例患者的节省费用,并进行单因素敏感性分析。
- 采用标准每QALY 10万美元和5万美元的阈值。
诊断标准与关键数值
- SBRT方案中MR-IGRT每疗程增加成本1459美元,常规分割放疗每疗程增加成本10129美元。
- SBRT在每QALY 10万美元和5万美元阈值下分别需相对降低毒性7%和14%才具成本效益。
- 常规分割放疗需相对降低毒性50%和94%才具成本效益。
临床应用与阅片要点
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To determine the toxicity reduction required to justify the added costs of MRI-guided radiotherapy (MR-IGRT) over CT-based image guided radiotherapy (CT-IGRT) for the treatment of localized prostate cancer.
METHODS: The costs of delivering prostate cancer radiotherapy with MR-IGRT and CT-IGRT in conventional 39 fractions and stereotactic body radiotherapy (SBRT) 5 fractions schedules were determined using literature values and cost accounting from two institutions. Gastrointestinal and genitourinary toxicity rates associated with CT-IGRT were summarized from 20 studies. Toxicity-related costs and utilities were obtained from literature values and cost databases. Markov modeling was used to determine the savings per patient for every 1% relative reduction in acute and chronic toxicities by MR-IGRT over 15 years. The costs and quality adjusted life years (QALYs) saved with toxicity reduction were juxtaposed with the cost increase of MR-IGRT to determine toxicity reduction thresholds for cost-effectiveness. One way sensitivity analyses were performed. Standard $100,000 and $50,000 per QALY ratios were used.
RESULTS: The added cost of MR-IGRT was $1,459 per course of SBRT and $10,129 per course of conventionally fractionated radiotherapy. Relative toxicity reductions of 7 and 14% are required for SBRT to be cost-effective using $100,000 and $50,000 per QALY, respectively. Conventional radiotherapy requires relative toxicity reductions of 50 and 94% to be cost-effective.
CONCLUSION: From a healthcare perspective, MR-IGRT can reasonably be expected to be cost-effective. Hypofractionated schedules, such a five fraction SBRT, are most likely to be cost-effective as they require only slight reductions in toxicity (7-14%).
ADVANCES IN KNOWLEDGE: This is the first detailed economic assessment of MR-IGRT, and it suggests that MR-IGRT can be cost-effective for prostate cancer treatment through toxicity reduction alone.
引用
- Schumacher LD, Dal Pra A, Hoffe SE, et al. Toxicity reduction required for MRI-guided radiotherapy to be cost-effective in the treatment of localized prostate cancer. Br J Radiol. 2020. PMID: 32783629. doi:10.1259/bjr.20200028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。